UBS Group
IBO

UBS Group’s Impact BioMedical IBO Stock Holding History

UBS Group’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.4K Buy
32,417
+30,248
+1,395% +$15.1K ﹤0.01% 7952
2025
Q4 		$1.09K Sell
2,169
-17,919
-89% -$9.48K ﹤0.01% 9705
2025
Q3 		$13.4K Sell
20,088
-19,637
-49% -$12.4K ﹤0.01% 8401
2025
Q2 		$25.7K Buy
39,725
+23,558
+146% +$13.2K ﹤0.01% 8282
2025
Q1 		$14.1K Buy
16,167
+11,915
+280% +$20.6K ﹤0.01% 8444
2024
Q4 		$6.17K Buy
4,252
+4,249
+141,633% +$8.81K ﹤0.01% 8588
2024
Q3 		$6 Buy
+3
New +$7 ﹤0.01% 9381

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's IBO Position: Q1 2026 in Review

UBS Group increased its Impact BioMedical (IBO) stake by 1,395% in Q1 2026, buying an estimated $15.1K and bringing the position to 32,417 shares worth $19.4K. The position accounts for ﹤0.01% of the portfolio, ranked #7952.

UBS Group first reported a position in IBO in Q3 2024 and has held it in 7 quarters since. The position peaked at $25.7K in Q2 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • UBS Group held 32,417 shares of Impact BioMedical worth $19.4K as of Q1 2026.
  • UBS Group bought 30,248 Impact BioMedical shares in Q1 2026, an estimated $15.1K.
  • Impact BioMedical made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7952 holding.
  • UBS Group first reported a position in Impact BioMedical in Q3 2024 and has held it in 7 quarters since.
  • UBS Group's Impact BioMedical position peaked at $25.7K in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.